/compare — side-by-sideLOADING
Valuation, growth, margins and forensic scores side-by-side — computed from each company's own SEC filings and last EOD close. No estimates, no fluff.
| Metric | BCRXBIOCRYST PHARMACEUTI |
|---|---|
| Last close | $8.57close 2026-11-03 |
| Change % | +3.94%close 2026-11-03 |
| Market cap | $2.2Bclose 2026-11-03 |
| P/E | 7.1FY to 2025-12-31 |
| Revenue | $875M⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldRevenueFromContractWithCustomerIncludingAssessedTax As ofFY ending 2025-12-31 Filing10-K · 0001628280-26-012240 · filed 2026-02-26 Open the filing on EDGAR → |
Fundamentals from XBRL company facts (as filed); market cap & P/E use last EOD close. Each cell names its period. A ratio row reads not comparable when the companies’ periods differ by more than six weeks or mix a fiscal year with a trailing twelve months, and a figure more than a year older than the company’s newest period is marked older period. No row ranks the companies. Educational only, not investment advice.
| Rev growth (YoY) | 94.1%FY to 2025-12-31 |
| Net income | $264M⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldNetIncomeLoss As ofFY ending 2025-12-31 FilingDEF 14A · 0001628280-26-026822 · filed 2026-04-23 Open the filing on EDGAR →Open the XBRL payload →CiteBIOCRYST PHARMACEUTICALS INC (BCRX), us-gaap:NetIncomeLoss: 263,861,000 USD, fiscal year ended 2025-12-31. Form DEF 14A, accession 0001628280-26-026822, filed 2026-04-23. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0000882796/us-gaap/NetIncomeLoss.json |
| Net margin | 30.2%FY to 2025-12-31 |
| EPS (diluted) | $1.21⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldEarningsPerShareDiluted As ofFY ending 2025-12-31 Filing10-K · 0001628280-26-012240 · filed 2026-02-26 Open the filing on EDGAR →Open the XBRL payload →CiteBIOCRYST PHARMACEUTICALS INC (BCRX), us-gaap:EarningsPerShareDiluted: 1.21 USD per share, fiscal year ended 2025-12-31. Form 10-K, accession 0001628280-26-012240, filed 2026-02-26. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0000882796/us-gaap/EarningsPerShareDiluted.json |
| Piotroski F-ScoreUNVALIDATED | 3FY to 2017-12-31, older period |
| Altman Z-ScoreUNVALIDATED | 8.36FY to 2017-12-31, older period |
| Beneish M-ScoreUNVALIDATED | inputs not filed |
| Next earnings | 02-20 → 03-02 |